Summary & Overview
HCPCS J9216: Injection, Interferon Gamma-1b, 3 Million Units
HCPCS Level II code J9216 denotes the injectable dose of interferon gamma 1-b (3 million units). This code captures administration of a biologic immunomodulator used in select clinical indications and is relevant to billing for outpatient injection and infusion services across the health system. Nationally, accurate coding for injectable biologics like interferon gamma 1-b matters for clinical documentation, reimbursement consistency, and drug utilization tracking.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise national overview of the code’s clinical context, typical sites of service, and which major payers are included in coverage considerations. The publication outlines where to find benchmarks and policy updates and summarizes billing considerations specific to injectable biologic therapies.
The report provides benchmarks for utilization and reimbursement (where available), recent policy or coverage guidance summaries, and practical coding context to support claims submission and audit readiness. Data elements not provided in the input are identified as unavailable so readers understand the scope and limitations of the analysis.
Billing Code Overview
HCPCS Level II code J9216 describes the injection of interferon, gamma 1-b, 3 million units. This code represents a parenteral biologic therapy dose administered as an injectable drug product. The service type is injectable biologic therapy, and the typical site of service is outpatient infusion or injection setting, including hospital outpatient departments, physician offices, and ambulatory infusion centers.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult receiving subcutaneous or intramuscular injection of interferon gamma-1b (J9216, 3 million units) for an FDA-approved indication such as chronic granulomatous disease (CGD) to reduce serious infections. The clinical workflow begins with a specialty provider visit (infectious disease, immunology, or hematology) documenting the indication, weight and dosing schedule, and obtaining baseline labs. Nursing or trained home health staff prepare and administer the dose in an outpatient clinic, infusion center, or patient home. Pre-administration tasks include verification of the medication and lot, review of allergies and prior adverse reactions, assessment of vital signs, and patient education about expected side effects (fever, injection-site reaction, myalgia). Post-injection monitoring includes observation for acute hypersensitivity for 15–30 minutes, documentation of lot number and administration site, and scheduling of follow-up dosing and lab monitoring (complete blood count, liver function tests) per protocol. Billing uses the HCPCS Level II code J9216 for the drug; administration and encounter services are billed separately using appropriate CPT/HCPCS administration or evaluation codes.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered |